Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?

References

• Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665–1671
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT, 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ, Investigators CREDO. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 288: 2411–2420
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527–533
   PubMed Web of Science ®Google Scholar
• Berger PB. Results of the Ticlid or Plavix Post-Stents (TOPPS) trial: Do they justify the switch from ticlopidine to clopidogrel after coronary stent placement?. Curr Control Trials Cardiovasc Med 2000; 1: 83–87
   PubMedGoogle Scholar
• Järemo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252: 233–238
   PubMed Web of Science ®Google Scholar
• Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, Lafont A, Camoin L, Walter U, Eigenthaler M. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295–302
   PubMed Web of Science ®Google Scholar
• Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171–3175
   PubMed Web of Science ®Google Scholar
• Aradi D, Komócsi A, Vorobcsuk A, Rideg O, Tokés-Füzesi M, Magyarlaki T, Horváth IG, Serebruany VL. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. Am Heart J 2010; 160: 543–551
   PubMed Web of Science ®Google Scholar
• Samara WM, Bliden KP, Tantry US, Gurbel PA. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb Res 2005; 115: 89–94
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919–933
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820–1826
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246–251
   PubMed Web of Science ®Google Scholar
• Verstuyft C, Tabassome S, Kim RB. Personalized medicine and antiplatelet therapy: Ready for prime time?. Eur Heart J 2009; 30: 1943–1963
   PubMed Web of Science ®Google Scholar
• Serebruany V, Cherala G, Williams C, Surigin S, Booze C, Kuliczkowski W, Atar D. Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of “resistance”. Am Heart J 2009; 158: 925–932
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303: 754–762
   PubMed Web of Science ®Google Scholar
• Trenk D, Hochholzer W, Fromm MF, Zolk O, Valina CM, Stratz C, Neumann FJ. Paraoxonase-1 Q192R Polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 2011, Jun 17 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Bernlochner I, Steinhubl S, Braun S, Morath T, Jaitner J, Stegherr J, Mehilli J, von Beckerath N, Schömig A, Kastrati A, et al. Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost 2010; 104: 1193–2000
   PubMed Web of Science ®Google Scholar
• Frelinger AL, 3rd, Michelson AD, Wiviott SD, Trenk D, Neumann FJ, Miller DL, Jakubowski JA, Costigan TM, McCabe CH, Antman EM, et al. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost 2011; 106: 219–226
   PubMedGoogle Scholar
• Siller-Matula JM, Jilma B, Schrör K, Christ G, Huber K. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: A systematic review and meta-analysis. J Thromb Haemost 2010; 8: 2624–2641
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: A pharmacogenetic analysis. Lancet 2010; 376: 1312–1319
   PubMed Web of Science ®Google Scholar
• Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. JAMA 2010; 304: 1821–1830
   PubMed Web of Science ®Google Scholar
• Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schömig A, Schömig E. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80: 486–501
   PubMed Web of Science ®Google Scholar
• Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg PG, Shah SH, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: A genetic substudy of the PLATO trial. Lancet 2010; 376: 1320–1328
   PubMed Web of Science ®Google Scholar
• Rideg O, Komócsi A, Magyarlaki T, Tőkés-Füzesi M, Miseta A, Kovács GL, Aradi D. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Pharmacogenomics., 2011 Aug 1. [Epub ahead of print]
   Google Scholar
• Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57: 2474–2483
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363–375
   PubMed Web of Science ®Google Scholar
• Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010; 121: 512–518
   PubMed Web of Science ®Google Scholar
• Bouman HJ, Harmsze AM, van Werkum JW, Breet NJ, Bergmeijer TO, Ten Cate H, Hackeng CM, Deneer VH, Ten Berg JM. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart 2011; 97: 1239–1244
   PubMed Web of Science ®Google Scholar
• Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Büttner HJ, Neumann FJ. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 2010; 55: 2427–2434
   PubMed Web of Science ®Google Scholar
• Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849–857
   PubMed Web of Science ®Google Scholar
• Bouman HJ, Schömig E, van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, Waldmann C, Schmalz HG, ten Berg JM, Taubert D. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011; 17: 110–116
   PubMed Web of Science ®Google Scholar
• Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Eur Heart J 2011; 32: 1605–13
   PubMed Web of Science ®Google Scholar
• Fontana P, James R, Barazer I, Berdagué P, Schved JF, Rebsamen M, Vuilleumier N, Reny JL. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study. J Thromb Haemost 2011; 9: 1664–1666
   PubMed Web of Science ®Google Scholar
• Wright RS, Anderson JL, Adams CD, Bridges CR, Casey Jr DE, Ettinger SM, Fesmire FM, Ganiats TG, Jneid H, Lincoff AM, et al. 2011 ACCF/AHA Focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;57:1920–1959
   Google Scholar
• European Association for Percutaneous Cardiovascular Interventions, Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31:2501–2555
   Google Scholar
• Silber S, Albertsson P, Avilés FF, Camici PG, Colombo A, Hamm C, Jørgensen E, Marco J, Nordrehaug JE, Ruzyllo W, et al. Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26: 804–847
   PubMed Web of Science ®Google Scholar
• ACC/AHA/SCAI 2005 Guideline update for percutaneous coronary intervention-summary article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006;47:216–235
   Google Scholar
• Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, et al. GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 2011; 305: 1097–1105
   PubMed Web of Science ®Google Scholar
• Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010; 103: 841–848
   PubMed Web of Science ®Google Scholar
• Combescure C, Fontana P, Mallouk N, Berdague P, Labruyere C, Barazer I, Gris JC, Laporte S, Fabbro-Peray P, Reny JL. Clinical implications of clopidogrel non-response in cardiovascular patients: A systematic review and meta-analysis. J Thromb Haemost 2010; 8: 923–933
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Acceptance of high platelet reactivity as a risk factor: Now, what do we do about it?. JACC Cardiovasc Interv 2010; 3: 1008–1010
   PubMedGoogle Scholar
• Sibbing D, Steinhubl SR, Schulz S, Schömig A, Kastrati A. Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: Initial evidence of a therapeutic window. J Am Coll Cardiol 2010; 56: 317–318
   PubMed Web of Science ®Google Scholar
• Aradi D, Vorobcsuk A, Lenkey Z, Horváth IG, Komócsi A. Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity. Platelets 2010; 21: 1–10
   PubMed Web of Science ®Google Scholar
• Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 1404–1411
   PubMed Web of Science ®Google Scholar
• Aradi D, Rideg O, Vorobcsuk A, Magyarlaki T, Magyari B, Kónyi A, Pintér T, Horváth IG, Komócsi A. Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity Eur J Clin Invest 2011, in press.
   Google Scholar
• Ari H, Ozkan H, Karacinar A, Ari S, Koca V, Bozat T. The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (The EFFICIENT Trial). Int J Cardiol 2011, Jan 14 [E-pub ahead of print]
   Google Scholar
• Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: Results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study. Circulation 2009; 119: 3215–3222
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Dimitropoulos G, Davlouros P, Xanthopoulou I, Kassimis G, Stavrou EF, Hahalis G, Athanassiadou A. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel. The importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 2011; 4: 403–410
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: The RESPOND study. Circulation 2010; 121: 1188–1199
   PubMed Web of Science ®Google Scholar
• Price MJ, Murray SS, Angiolillo DJ, et al. Primary results from genotype information and functional testing a prospective pharmacogenomic analysis of clopidogrel therapy. Presented at American College of Cardiology Meeting 2011, 1–5 April 2001, New Orleans, LA, USA
   Google Scholar